Dyax — Merger or Acquisition (November 2015)
21 slides from Dyax's merger presentation, Nov 2, 2015
Slide 1: Shire to Acquire Dyax Corp.
Shire to Acquire Dyax Corp. Further step in building a leading biotech in rare diseases Extends and expands HAE leadership position Enhances growth and delivers significant value for shareholders Flemming Ornskov, MD, MPH CEO, Shire plc Jeff Poulton CFO, Shire plc Gustav A. Christensen President and
Slide 2: Forward Looking Statements
Forward Looking Statements Statements included herein that are not historical facts, including without limitation statements concerning our proposed acquisition of Dyax Corp. (Dyax) and the timing and financial and strategic benefits thereof, the anticipated timing of clinical trials and approval, a
Slide 3: Forward Looking Statements
Forward Looking Statements failure to achieve Shire?s strategic objectives with respect to the acquisition of NPS Pharmaceuticals Inc. and Dyax may adversely affect Shire?s financial condition and results of operations; Shire’s strategy to acquire Baxalta may not be successful: Baxalta may refuse to
Slide 4: Clear Strategic Rationale
Clear Strategic Rationale • Aligns with Shire’s strategy to build a leading biotech company focused on rare diseases o Best-in-class therapies for diseases with significant unmet need o Lever M&A to enhance portfolio and capabilities in core therapeutic areas • Represents a clear strategic fit withi
Slide 5: Building a Leading Biotech Focused on Innovative Best-In-Class Therapies
Building a Leading Biotech Focused on Innovative Best-In-Class Therapies Addressing Significant Unmet Needs Complement Biology •Cinryze NMO •Cinryze SC •rC1-INH Renal / Fibrotic •Maribavir •Cinryze AMR •Fibrotech (FSGS) •CF (MRT) •DEB Rare Diseases Leadership Select in-line and pipeline assets CNS •
Slide 6: Dyax Enhances the Range of Shire's Indications Related to Complement Biology
Dyax Enhances the Range of Shire’s Indications Related to Complement Biology Complement system biology Example indications: HAE Prophylaxis Acute Shire presence: DX-2930 In development for prophylaxis 1. Antibody mediated rejection. macular degeneration Neurology • NMO • Myasthenia gravis • MS In de
Slide 7: Building a Leading HAE Franchise
[GRAPHIC APPEARS HERE] [GRAPHIC APPEARS HERE] Building a Leading HAE Franchise Cinryze/Firazyr Worldwide Revenues 1000 900 800 700 600 500 400 300 200 100 0 $-Millions ViroPharma acquisition 2011: US Firazyr launch ~33% 9/30/15 YTD Cinryze Launch; y/y growth at Jerini acquisition; constant F/X EU Fi
Slide 8: Background on Dyax Corp.
[GRAPHIC APPEARS HERE] [GRAPHIC APPEARS HERE] Background on Dyax Corp. (NASDAQ: DYAX) History • Founded in 1995 and listed on NASDAQ since 2000 • Headquarters in Burlington, Massachusetts • 2014 revenues of U.S.$81.7M • 150 employees including 62 in R&D and 25 field-based HAE Portfolio • Focused on
Slide 9: Hereditary Angioedema: A Rare, Devastating Disease
Hereditary Angioedema: A Rare, Devastating Disease Rare genetic disease of the immune system caused by a deficiency of C1-INH activity that inhibits pKal, a key mediator of inflammation Affects 1:40k people globally (~42,000) [GRAPHIC APPEARS HERE] Attacks can be frequent (1-2 times per week) and af
Slide 10: Future HAE Market Growth Potential
Future HAE Market Growth Potential • 60% of global HAE patients undiagnosed; 30-40% in U.S./EU • Prophylactic treatment likely underutilized (up to 40% of U.S./EU treated patients still on acute treatment only) • More convenient regimens with greater efficacy could provide improved control of curren
Slide 11: DX-2930 Phase 1b Trial: Key Efficacy and Safety Data
DX-2930 Phase 1b Trial: Key Efficacy and Safety Data Observed attack rates (versus placebo) • Phase 1b study in HAE patients who reported having at least 2 HAE attacks in the 3 months prior to study entry [GRAPHIC APPEARS HERE] • Pre-specified, primary efficacy interval of 6 weeks • HAE attack rate
Slide 12: DX-2930 Phase 1b patient attack and concentration data
DX-2930 (ng/mL) 0 10,000 20,000 30,000 40,000 50,000 300 mg Historically: 9 attacks in last 3 months -45 5 55 105 Study Day DX-2930 (ng/mL) 0 10,000 20,000 30,000 40,000 50,000 400 mg Historically: 36 attacks in last 3 months attack DX-2930 -45 5 55 105 DX-2930 (ng/mL) 0 10,000 20,000 30,000 40,000
Slide 13: DX-2930: Next-generation Development in HAE Prophylaxis
DX-2930: Next-generation Development in HAE Prophylaxis • Phase 3-ready, long-acting injectable for HAE prophylaxis, with the potential for improved efficacy and convenience • Patent and anticipated regulatory exclusivity beyond 2030 • Fast Track, Breakthrough Therapy and Orphan Drug designations by
Slide 14: Demand for Improved Convenience and Greater Efficacy
Demand for Improved Convenience and Greater Efficacy • Physicians and patients consider more convenient dosing/routes of administration/ frequency of dosing to be the key unmet needs in HAE prophylaxis Patient / • Improvement in efficacy rates beyond current 50-60% reductions in attacks is desired P
Slide 15: Potential Opportunities from Dyax's Preclinical Pipeline
Potential Opportunities from Dyax’s Preclinical Pipeline DX-2930 for diabetic DX-2507 for antibody- DX-4012 as an macular edema (DME) mediated autoimmune disease anti-thrombotic therapy • Fully human monoclonal antibody to • Fully human monoclonal antibody to • Fully human monoclonal antibody to pla
Slide 16: Transaction Details
Transaction Details • $37.30 in cash per Dyax share, for aggregate upfront cash consideration of $5.9 billion Consideration • CVR that will pay an additional $4.00 in cash per Dyax share upon potential FDA approval of DX-2930 in Type 1 and Type 2 HAE and prior to 31 December 2019, representing a pot
Slide 17: Additional Remarks
Additional Remarks Gustav A. Christensen President and CEO, Dyax Corp. 17
Slide 18: Clear Strategic Rationale
Clear Strategic Rationale • Aligns with Shire’s strategy to build a leading biotech company focused on rare diseases o Best-in-class therapies for diseases with significant unmet need o Lever M&A to enhance portfolio and capabilities in core therapeutic areas • Represents a clear strategic fit withi
Slide 19: Q&A
Q&A Flemming Ornskov, MD, MPH CEO, Shire plc Jeff Poulton CFO, Shire plc Phil Vickers, PhD Head of Research and Development, Shire plc Mark Enyedy Head of Corporate Development, Shire plc
Slide 20: Cautionary Statement Regarding Forward-Looking Statements
Cautionary Statement Regarding Forward-Looking Statements Certain statements in this communication may contain certain “forward-looking statements” (including “forward-looking statements” within the meaning of the Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securiti
Slide 21: Additional Information and Where to Find It
Additional Information and Where to Find It In connection with the merger, the Company will prepare a proxy statement to be filed with the SEC. When completed, a definitive proxy statement and a form of proxy will be mailed to the stockholders of the Company. BEFORE MAKING ANY VOTING DECISION, THE C